MSI-H And dMMR Market Forecast Highlights Expansion From $9.31 Billion To $21.12 Billion Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
MSI-H And dMMR Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for MSI-H and dMMR has experienced exponential expansion in recent years. Projected to increase from $7.57 billion in 2025 to $9.32 billion in 2026, this represents a compound annual growth rate (CAGR) of 23.1%. Several factors have driven growth during the historical period, including the identification of MSI-H and dMMR biomarkers, the initial effectiveness of immune checkpoint inhibitors, a growing incidence of colorectal and endometrial cancers, the broadening use of molecular diagnostic tools, and the regulatory endorsement of therapies targeting these biomarkers.
The msi-h and dmmr market size is projected to undergo exponential expansion over the coming years, reaching $21.13 billion by 2030 with a compound annual growth rate (CAGR) of 22.7%. This growth during the forecast period is driven by factors such as the rising adoption of precision oncology, the increased application of genomic testing in cancer care, the broadening of immunotherapy indications, heightened investment in biomarker research, and accumulating clinical evidence that supports tumor-agnostic strategies. Key trends shaping this period include the growing adoption of immunotherapy for msi-h and dmmr tumors, the expanding use of companion diagnostics to stratify patients, an increasing emphasis on tumor-agnostic cancer therapies, the development of combination immunotherapy protocols, and heightened awareness surrounding biomarker-driven oncology.
Download A Free Sample Report For Comprehensive Market Insights:
MSI-H And dMMR Market Demand Drivers: What Is Fueling Industry Growth?
The growing incidence of cancer is expected to drive expansion in the MSI-H and dMMR market in the coming years. Cancer encompasses a range of diseases marked by the unregulated proliferation and dissemination of abnormal cells throughout the body. This upward trend in cancer cases is largely attributed to aging populations, given that the likelihood of developing cancer escalates significantly with age, stemming from the buildup of genetic mutations and extended exposure to risk factors over time. MSI-H and dMMR are utilized in oncology to detect tumors exhibiting high mutation rates due to impairments in DNA repair mechanisms. These biomarkers assist in steering immunotherapy strategies, since such tumors tend to respond favorably to immune checkpoint inhibitors, while also offering clues about prognosis and potential hereditary conditions. For example, in January 2024, the American Cancer Society—a US nonprofit organization—reported that approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths were forecast for 2023 in the United States. These figures are expected to grow in 2024, with around 2,001,140 new cases and 611,720 deaths predicted, underscoring a sustained rise in both cancer occurrence and mortality. As a result, the escalating prevalence of cancer is fueling momentum in the MSI-H and dMMR market.
MSI-H And dMMR Market Segment Outlook: Which Categories Are Expanding The Fastest?
The msi-h and dmmr market covered in this report is segmented –
1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy
2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications
3) By Stage: Early Stages, Advanced Stages
4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare
Subsegments:
1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies
MSI-H And dMMR Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the MSI-H and dMMR market are concentrating on the creation of novel therapies, including combination strategies, to boost treatment effectiveness and improve outcomes for patients. For MSI-H and dMMR cancers, combination therapy integrates two or more treatment methods, frequently immune checkpoint inhibitors or a mix of immunotherapy with chemotherapy, targeted therapies, or radiation. This strategy is intended to heighten treatment responses, counteract resistance, and extend survival for individuals with tumors characterized by high microsatellite instability or deficient mismatch repair. A notable example occurred in April 2025 when Bristol-Myers Squibb Company, a pharmaceutical firm based in the United States, secured approval from the United States Food and Drug Administration (FDA) for the combined use of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line intervention for metastatic colorectal cancer (mCRC) displaying MSI-H or dMMR properties, thereby broadening therapeutic possibilities for this difficult cancer type. This authorization represents a major advancement in managing MSI-H and dMMR cancers by introducing an effective new option that engages multiple pathways to elevate patient survival and response rates, thereby fulfilling the unmet needs of this patient segment.
MSI-H And dMMR Market Key Companies And Competitive Benchmarking
Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.
Access The Complete MSI-H And dMMR Market Report:
MSI-H And dMMR Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
